India, July 11 -- The pharmaceutical industry has increasingly shifted toward the Contract Development and Manufacturing Organization (CDMO) model, where drug innovators outsource research, process development, clinical manufacturing and commercial production to specialized manufacturing partners. Instead of investing billions of dollars in manufacturing infrastructure, global pharmaceutical companies are increasingly partnering with CDMOs to accelerate drug development, reduce costs and improve operational flexibility.

India has become one of the world's preferred outsourcing destinations due to its large pool of scientific talent, globally compliant manufacturing facilities and significantly lower production costs compared to develope...